Journal Information
Vol. 88. Issue 4.
Pages 435-436 (October - December 2023)
Vol. 88. Issue 4.
Pages 435-436 (October - December 2023)
Scientific letter
Full text access
Ménétrier disease: A rare cause of hypertrophic gastropathy
Enfermedad de Ménétrier: una causa rara de gastropatía hipertrófica
C.E. Alcántara-Figueroaa,b,
Corresponding author

Corresponding author at: Calle Los Manzanos Mz. G Lote 5 A, Dpto. 602, Urb. El Golf, distrito Víctor Larco Herrera, Trujillo, La Libertad, Peru, Tel.: +51969672075.
, D.C. Calderón-Cabrerab, Y.K. Pariona-Martínezc, R. de la Cruz-Rojasd, R.A. Alcántara-Ascóna
a Escuela de Medicina, Universidad Privada Antenor Orrego, Trujillo, La Libertad, Peru
b Servicio de Gastroenterología, Hospital Belén, Trujillo, La Libertad, Peru
c Escuela de Administración, Universidad César Vallejo, Trujillo, La Libertad, Peru
d Escuela de Medicina, Universidad César Vallejo, Trujillo, La Libertad, Peru
This item has received
Article information
Full Text
Download PDF
Figures (1)
Full Text

Ménétrier disease (MD) is an enteropathy characterized by gastric fold hyperplasia and a state of protein loss. Pharmacologic treatment has shown varying results, and in cases of refractoriness, gastrectomy is a therapeutic option.1,2

A 58-year-old woman with 4-month progression of the disease presented with mild epigastralgia, nausea, and lower limb edema. Laboratory work-up reported Hb 10g/dl, total protein 4.8g/dl, and albumin 2.9g/dl. Endoscopy revealed multiple hypertrophic folds in the gastric body, resembling “circumvolutions” with mucus (Fig. 1A and B), and erosions at the level of the antrum (Fig. 1C). The anatomopathologic study reported marked foveolar hyperplasia, tortuous foveolar glands, and multiple cystic dilations (Fig. 1D), as well as the presence of Helicobacter pylori. Extended-release octreotide was administered at a dose of 20mg IM monthly, for 4 months, along with 1g of amoxicillin every 12h and 500mg of levofloxacin every 24h for 14 days, for Helicobacter pylori eradication, and 40mg of esomeprazole every 12h for 4 months. The eradication of the bacterium was verified. Given the lack of clinical and endoscopic improvement, monoclonal antibodies were considered the best option. However, those medications are not available at our hospital, and so total gastrectomy was performed. The patient’s progression was favorable at the follow-up at one year.

Figure 1.

(A) Gastric body showing giant hypertrophic folds. (B) Folds with mucus secretions. (C) Gastric antrum with erosions. (D) Histologic study showing marked foveolar hyperplasia and cystic dilations.


MD is a gastropathy characterized by gastric fold hypertrophy, with protein loss. It affects middle-aged men3 and is associated with gastric adenocarcinoma in 6–10% of cases.4

The disease is related to higher alpha-TGF production and epithelial cell proliferation that produce abundant mucus. The hypersecretion of mucus causes malabsorption of nutrients, electrolytes, and vitamins. Ninety percent of cases are associated with Helicobacter pylori.3,4

The clinical manifestations are epigastralgia (65%), anorexia (45%), weight loss (45%), edema (38%), and vomiting (38%); diarrhea and gastrointestinal bleeding are less frequent.3,5

Laboratory findings include hypoalbuminemia, elevated serum gastrin levels, and iron-deficiency anemia.5 Endoscopy identifies hypertrophic gastric folds that do not affect the antrum. Histologic study describes foveolar hyperplasia, oxyntic gland atrophy, and a decrease in parietal cells, as well as edema and smooth muscle hyperplasia in the lamina propria.6,7 The differential diagnosis in hypertrophic gastropathy should include infections due to cytomegalovirus and syphilis; tumors, such as adenocarcinoma, lymphoma, and Zollinger-Ellison syndrome; infiltrative diseases, such as sarcoidosis and amyloidosis; and other causes, such as eosinophilic gastroenteritis.6 Treatment includes a protein-rich diet, proton pump inhibitors, and macronutrient replacement. Octreotide has been shown to be beneficial in some patients, but in refractory cases, total gastrectomy is recommended, as in the case of our patient.8,9

In conclusion, MD is a form of hypertrophic gastropathy that presents with digestive symptoms and protein loss. In medical treatment-refractory cases, total gastrectomy should be considered an option.

Ethical considerations

The authors declare that no experiments were conducted on humans for this research. We utilized the protocols for obtaining patient information from our work center’s database, preserving patient anonymity, so informed consent was not requested. This study meets the current bioethical research regulations.

Financial support

No financial support was received in relation to this article.

Conflict of interest

The authors declare that there is no conflict of interest.

M.U. Kamal, H. Tariq, V. Mehak, et al.
A rare etiology of abnormally large gastric folds: Menetrier’s disease.
Case Rep Gastrointest Med, (2019),
S. Thapa, A. Ghosh, G. Pun, et al.
A misdiagnosed case of hypertrophic gastropathy.
I.H. Hassan, M. Soliman, A.R. Shirazi-Nejad, et al.
Ménétrier’s disease and its atypical presentation in four siblings.
P. Pepa, T. Uehara, A. Wonaga, et al.
Menetrier’s disease. A diagnostic and therapeutic challenge.
Medicina (B Aires), 81 (2021), pp. 470-473
D.R. Waisberg, E. Sobroza-de Mello, F. Tustumi, et al.
A case report of diffuse hyperplastic gastropathy with multiple polypoid formations in a patient with pernicious anemia, Helicobacter pylori infection, hypergastrinemia and hypoalbuminaemia: Do not forget of Ménétrier’s disease.
Int J Surg Case Rep, 77 (2020), pp. 498-502
R. Agarwala, J. Shah, U. Dutta.
Thickened gastric folds: approach.
J Dig Endosc, 09 (2018), pp. 149-154
H.-H. Wang, C.-C. Zhao, X.-L. Wang, et al.
Menetrier’s disease and differential diagnosis: A case report.
World J Clin Cases, 9 (2021), pp. 6943-6949
G. Nunes, R. Barosa, M. Patita, et al.
Ménétrier’s disease: a case of successful treatment using long-acting octreotide.
Acta Gastroenterol Belg, 82 (2019), pp. 429-432
C. Parianos, C. Aggeli, A. Sourla, et al.
Total gastrectomy for the treatment of Menetrier’s disease persistent to medical therapy: a case report.
Int J Surg Case Rep, 73 (2020), pp. 95-99

Please cite this article as: Alcántara-Figueroa CE, Calderón-Cabrera DC, Pariona-Martínez YK, de la Cruz-Rojas R, Alcántara-Ascón RA. Enfermedad de Ménétrier: una causa rara de gastropatía hipertrófica. Rev Gastroenterol Mex. 2023;88:435–436.

Revista de Gastroenterología de México
Article options
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.